| Expression pattern: |
DN |
| Associated gene: |
PARP1, beta-catenin, TCF4 |
| Associated microRNA: |
- |
| Biological function: |
Inhibits GC cell proliferation and migration; induces G2/M cell cycle arrest; suppresses tumor growth in vivo. |
| Molecular mechanism: |
circATM binds PARP1 (ZFⅡ-Ⅲ) to block recruitment to DNA damage sites and promote ubiquitin-proteasome degradation of PARP1; disrupts PARP1/beta-catenin/TCF4 complex, suppressing Wnt/beta-catenin transcriptional activity. |
| Biological pathway or process: |
Wnt/beta-catenin (inhibits); cell cycle (inhibits); proliferation (inhibits); migration (inhibits); ubiquitination (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
circRNA-seq; RT-qPCR; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; Nuclear-Cytoplasmic Fractionation; RNA Pull-Down; RIP (RNA Immunoprecipitation); Co-IP; Luciferase Reporter Assay; Transfection; EdU Staining; Colony Formation Assay; Wound Healing Assay; Cell Cycle Assay; In Vivo Animal Model; Western Blot; Bioinformatics Analysis |
| Clinical significance: |
circATM levels are negatively related to tumor aggressiveness (more lymph node metastases and poorer tumor differentiation) and proposed as a diagnostic/therapeutic biomarker for GC. |
| Description: |
circATM is down-regulated in gastric cancer and functions as a tumor suppressor. It binds PARP1 (ZFⅡ-Ⅲ), promotes PARP1 ubiquitin-proteasome degradation and disrupts the PARP1/beta-catenin/TCF4 transcriptional complex, thereby suppressing Wnt/beta-catenin signaling and inducing G2/M cell cycle arrest, reducing proliferation and migration in vitro and tumor growth in vivo. |
| Confidence score: |
0.8079 |